Funan Liu

655 total citations
25 papers, 444 citations indexed

About

Funan Liu is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Funan Liu has authored 25 papers receiving a total of 444 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pulmonary and Respiratory Medicine, 11 papers in Oncology and 9 papers in Molecular Biology. Recurrent topics in Funan Liu's work include Gastric Cancer Management and Outcomes (8 papers), Colorectal Cancer Treatments and Studies (5 papers) and Protein Kinase Regulation and GTPase Signaling (4 papers). Funan Liu is often cited by papers focused on Gastric Cancer Management and Outcomes (8 papers), Colorectal Cancer Treatments and Studies (5 papers) and Protein Kinase Regulation and GTPase Signaling (4 papers). Funan Liu collaborates with scholars based in China, Montenegro and Japan. Funan Liu's co-authors include Pengliang Wang, Feng Li, Baocheng Gong, Huimian Xu, Hanwei Huang, Lei Luo, Na Di, Zhi‐Feng Miao, Zhenguo Cheng and Zongmin Du and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Biochemical and Biophysical Research Communications.

In The Last Decade

Funan Liu

23 papers receiving 439 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Funan Liu China 13 224 153 118 106 92 25 444
Hang Lv China 15 249 1.1× 132 0.9× 152 1.3× 126 1.2× 84 0.9× 34 505
Yangwei Xu China 6 231 1.0× 111 0.7× 136 1.2× 117 1.1× 46 0.5× 12 440
Shuntai Chen China 10 161 0.7× 205 1.3× 91 0.8× 186 1.8× 174 1.9× 22 512
Mitsuhiro Miyazaki Japan 13 156 0.7× 137 0.9× 50 0.4× 100 0.9× 140 1.5× 22 397
Wenying Deng China 11 168 0.8× 116 0.8× 88 0.7× 123 1.2× 82 0.9× 34 372
C-W Wu Taiwan 10 283 1.3× 86 0.6× 159 1.3× 168 1.6× 102 1.1× 10 595
Guifang Lu China 14 405 1.8× 67 0.4× 325 2.8× 46 0.4× 83 0.9× 23 595
Chengjuan Zhang China 15 239 1.1× 123 0.8× 121 1.0× 174 1.6× 48 0.5× 39 477
E. Heath United States 8 395 1.8× 144 0.9× 149 1.3× 72 0.7× 102 1.1× 15 606
Fanming Kong China 12 226 1.0× 113 0.7× 96 0.8× 180 1.7× 62 0.7× 61 515

Countries citing papers authored by Funan Liu

Since Specialization
Citations

This map shows the geographic impact of Funan Liu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Funan Liu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Funan Liu more than expected).

Fields of papers citing papers by Funan Liu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Funan Liu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Funan Liu. The network helps show where Funan Liu may publish in the future.

Co-authorship network of co-authors of Funan Liu

This figure shows the co-authorship network connecting the top 25 collaborators of Funan Liu. A scholar is included among the top collaborators of Funan Liu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Funan Liu. Funan Liu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wang, Yu, et al.. (2024). Myasthenia gravis and myocarditis induced by chemoimmunotherapy in locally advanced gastric cancer: A case report. Experimental and Therapeutic Medicine. 28(5). 426–426. 1 indexed citations
2.
Wang, Xu, Xianbao Shi, Zhenguo Cheng, et al.. (2024). Bimetallic nanodot-adenovirus chimera for cancer theranostics via cooperativity of autophagy and ferroptosis. Cell Reports Physical Science. 5(10). 102221–102221. 1 indexed citations
3.
Tang, Qiyu, Dawei Wu, Huiyao Huang, et al.. (2023). Adverse events of PD-(L)1 inhibitors plus anti-VEGF(R) agents compared with PD-(L)1 inhibitors alone for cancer patients: a systematic review and meta-analysis. Frontiers in Pharmacology. 14. 1093194–1093194. 3 indexed citations
4.
Ji, Ke, Zhaode Bu, Zhenning Wang, et al.. (2023). Nab-paclitaxel combined with oxaliplatin and S-1 as conversion therapy for advanced gastric adenocarcinoma.. Journal of Clinical Oncology. 41(4_suppl). 343–343.
5.
6.
Pan, Siwei, Qi Gao, Qingchuan Chen, et al.. (2021). Integrative analysis-based identification and validation of a prognostic immune cell infiltration-based model for patients with advanced gastric cancer. International Immunopharmacology. 101(Pt B). 108258–108258. 6 indexed citations
7.
Pan, Siwei, Pengliang Wang, Hanwei Huang, et al.. (2019). A Proposal of a Personalized Surveillance Strategy for Gastric Cancer: A Retrospective Analysis of 9191 Patients. Gastroenterology Research and Practice. 2019. 1–9. 12 indexed citations
8.
Wang, Pengliang, Funan Liu, Hanwei Huang, et al.. (2019). Novel immune–risk score of gastric cancer: A molecular prediction model combining the value of immune–risk status and chemosensitivity. Cancer Medicine. 8(5). 2675–2685. 22 indexed citations
9.
Tong, Yuxin, Yan Li, Hui Gu, et al.. (2018). HSF1, in association with MORC2, downregulates ArgBP2 via the PRC2 family in gastric cancer cells. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1864(4). 1104–1114. 31 indexed citations
10.
Wang, Pengliang, Jinyu Huang, Zhi Zhu, et al.. (2018). Development of a risk-scoring system to evaluate the serosal invasion for macroscopic serosal invasion positive gastric cancer patients. European Journal of Surgical Oncology. 44(5). 600–606. 6 indexed citations
11.
Huang, Hanwei, Xiang‐Yu Zhang, Hailun Jiang, et al.. (2018). Structure activity relationships of chrysoeriol and analogs as dual c‑Met and VEGFR2 tyrosine kinase inhibitors. Oncology Reports. 40(3). 1650–1656. 12 indexed citations
12.
Gong, Baocheng, Yuan Li, Zhenguo Cheng, et al.. (2017). GRIK3: A novel oncogenic protein related to tumor TNM stage, lymph node metastasis, and poor prognosis of GC. Tumor Biology. 39(6). 3726132036–3726132036. 16 indexed citations
13.
Wang, Pengliang, et al.. (2017). A Nomogram for Predicting Overall Survival of Gastric Cancer Patients with Insufficient Lymph Nodes Examined. Journal of Gastrointestinal Surgery. 21(6). 947–956. 13 indexed citations
14.
Huang, Hanwei, Xiangyu Zhang, Hailun Jiang, et al.. (2017). Old drug new tricks: Chlorhexidine acts as a potential allosteric inhibitor toward PAK1. Biochemical and Biophysical Research Communications. 495(1). 728–732. 3 indexed citations
15.
Cheng, Zhenguo, et al.. (2014). miR-133 is a key negative regulator of CDC42–PAK pathway in gastric cancer. Cellular Signalling. 26(12). 2667–2673. 44 indexed citations
16.
Sun, Zhe, Zhenning Wang, Yingying Xu, et al.. (2012). Prognostic significance of tumor deposits in gastric cancer patients who underwent radical surgery. Surgery. 151(6). 871–881. 44 indexed citations
17.
18.
Li, Xiaodong, Funan Liu, & Feng Li. (2010). PAK as a therapeutic target in gastric cancer. Expert Opinion on Therapeutic Targets. 14(4). 419–433. 22 indexed citations
19.
Di, Na, Funan Liu, Zhi‐Feng Miao, Zongmin Du, & Huimian Xu. (2009). Astragalus extract inhibits destruction of gastric cancer cells to mesothelial cells by anti-apoptosis. World Journal of Gastroenterology. 15(5). 570–570. 41 indexed citations
20.
Liu, Funan, Xiaodong Li, Chunyu Wang, et al.. (2009). Downregulation of p21‐activated kinase‐1 inhibits the growth of gastric cancer cells involving cyclin B1. International Journal of Cancer. 125(11). 2511–2519. 48 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hang Lv Breakdown of academic impact, for papers by Yangwei Xu Breakdown of academic impact, for papers by Shuntai Chen Breakdown of academic impact, for papers by Mitsuhiro Miyazaki Breakdown of academic impact, for papers by Wenying Deng Breakdown of academic impact, for papers by C-W Wu Breakdown of academic impact, for papers by Guifang Lu Breakdown of academic impact, for papers by Chengjuan Zhang Breakdown of academic impact, for papers by E. Heath Breakdown of academic impact, for papers by Fanming Kong
Rankless by CCL
2026